FDA expedites review of BioMarin's rare-disease drug Vimizim

05/31/2013 | RTT News

The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A Syndrome. The enzyme replacement therapy was granted a priority-review status.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide